表紙
市場調查報告書

關注市場分析:大腸激躁症 (IBS)

Market Spotlight: Irritable Bowel Syndrome (IBS)

出版商 Datamonitor Healthcare 商品編碼 594579
出版日期 內容資訊 英文 50 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
關注市場分析:大腸激躁症 (IBS) Market Spotlight: Irritable Bowel Syndrome (IBS)
出版日期: 2019年11月27日內容資訊: 英文 50 Pages
簡介

本報告提供過敏性腸道症候群 (IBS)的治療藥市場相關分析,疾病概要和患者數的變化、預測,目前的主要的治療方法,法規環境和近幾年主要的事件,現在開發中臨床實驗的進展與上市計劃,主要的治療藥的市場趨勢預測 (今後10年份),資本交易的動向等調查。

分析的要點

疾病的背景情況

  • IBS的亞型

治療方法

  • 緩瀉劑
  • 止瀉藥
  • 解痙藥
  • 抗憂鬱劑
  • 血清素受體激動劑
  • 氯離子通道活化劑
  • 鳥糞嘌呤環化酶致效劑
  • 抗生素
  • 類鴉片物質受體
  • 益生菌

流行病學

已上市醫藥品

  • 各國的認證情形

開發平台上的醫藥品

將產生的主要事件

法規相關的主要的事件 (1件)

授權合約、資產收購交易

母體專利

商機

臨床實驗形勢

  • 贊助商數:各狀態
  • 贊助商數:各相位

相關分析

  • 處方藥的資訊

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0181355

This Market Spotlight report covers the irritable bowel syndrome (IBS) market, comprising key pipeline and marketed drugs, clinical trials, upcoming regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Datamonitor Healthcare estimates that in 2017, there were approximately 766 million prevalent cases of irritable bowel syndrome (IBS) in people aged 15 years and over worldwide, and forecasts that number to increase to 843 million prevalent cases by

2026. The approved drugs in the IBS space target chloride channel 2, calcium channel, sodium-hydrogen exchanger 3, serotonin 5- HT3 receptor, guanylyl cyclase c receptor, opioid receptors, gram-negative bacteria, RNA polymerase, and serotonin 5-HT4 receptor. These drugs are administered via the oral route.

The majority of industry-sponsored drugs in active clinical development for IBS are in Phase II.

Therapies in development for IBS focus on a wide variety of targets. All of the pipeline drugs are administered via the oral route.

The only high-impact upcoming event in the IBS space is the release of topline Phase II trial results for MD-7246. The overall likelihood of approval of a Phase I gastroenterology (non inflammatory bowel disease)-other asset is 21.9%, and the average probability a drug advances from Phase III is 66.7%. Drugs, on average, take 9.8 years from Phase I to approval, compared to 9.6 years in the overall gastroenterology (non inflammatory bowel disease) space.

There have been 20 licensing and asset acquisition deals involving IBS drugs during 2014-19. The $2,905m research, development, collaboration, and license agreement signed in 2017 between Allergan and Assembly Biosciences for the worldwide rights to Assembly's microbiome GI development programs was the largest deal.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for IBS have been in the early and midphases of development, with 65% of trials in Phase I-II, and only 35% in Phase III-IV.

The US has a substantial lead in the number of IBS clinical trials globally. The UK leads the major EU markets, while Japan has the top spot in Asia.

Clinical trial activity in the IBS space is dominated by completed trials. Allergan and GlaxoSmithKline have the highest number of completed clinical trials for IBS, with 37 trials each.

Allergan leads industry sponsors with the highest number of clinical trials for IBS, followed by GlaxoSmithKline.

TABLE OF CONTENTS

CONTENTS

6 OVERVIEW

7 KEY TAKEAWAYS

8 DISEASE BACKGROUND

8 Subtypes

9 TREATMENT

9 Laxatives

9 Antidiarrheal drugs

9 Antispasmodics

9 Antidepressants

9 Serotonin receptor agonists

10 Chloride channel activators

10 Guanylyl cyclase C agonists

10 Antibiotics

10 Opioid receptors

10 Probiotics

12 EPIDEMIOLOGY

18 MARKETED DRUGS

21 PIPELINE DRUGS

27 RECENT EVENTS AND ANALYST OPINION

27 Zelnorm for IBS (July 8, 2019)

27 Multiple Drugs for IBS (June 25, 2019)

28 Linzess for IBS (June 18, 2019)

30 IB-Stim for IBS (June 7, 2019)

31 Zelnorm for IBS (October 17, 2018)

32 Zelnorm for IBS (October 15, 2018)

35 KEY UPCOMING EVENTS

36 KEY REGULATORY EVENTS

36 Ardelyx Touts Ibsrela's Novel Mechanism Of Action For IBS-C

36 FDA Approves The First Device To Treat Pain Caused By IBS

36 Poland Switches from Rx-To-OTC Mylan's Duspatalin For IBS, Plus Orion's ED Treatment

36 Zelnorm Returning To US Market With Broad IBS-C Indication

38 PROBABILITY OF SUCCESS

39 LICENSING AND ASSET ACQUISITION DEALS

39 AstraZeneca Acquires All Linzess Rights In China

39 Alfasigma Acquires Sloan's Zelnorm

40 Deals Shaping The Medical Industry, January 2019

41 PARENT PATENTS

42 REVENUE OPPORTUNITY

43 CLINICAL TRIAL LANDSCAPE

44 Sponsors by status

45 Sponsors by phase

47 BIBLIOGRAPHY

48 Prescription information

49 APPENDIX

LIST OF FIGURES

  • 14 Figure 1: Trends in prevalent cases of IBS, 2017-26
  • 17 Figure 2: Prevalent cases of IBS, by age group, 2017
  • 21 Figure 3: Overview of pipeline drugs for IBS in the US
  • 22 Figure 4: Pipeline drugs for IBS, by company
  • 22 Figure 5: Pipeline drugs for IBS, by drug type
  • 22 Figure 6: Pipeline drugs for IBS, by classification
  • 30 Figure 7: Linzess for IBS (June 18, 2019): Phase IIIb - IBS-C Abdominal Symptoms
  • 34 Figure 8: Zelnorm for IBS (October 15, 2018)
  • 35 Figure 9: Key upcoming events in IBS
  • 38 Figure 10: Probability of success in the IBS pipeline
  • 39 Figure 11: Licensing and asset acquisition deals in IBS, 2014-19
  • 41 Figure 12: Parent patents in IBS
  • 43 Figure 13: Clinical trials in IBS
  • 43 Figure 14: Top 10 drugs for clinical trials in IBS
  • 44 Figure 15: Top 10 companies for clinical trials in IBS
  • 44 Figure 16: Trial locations in IBS
  • 45 Figure 17: IBS trials status
  • 46 Figure 18: IBS trials sponsors, by phase

LIST OF TABLES

  • 13 Table 1: Prevalent cases of IBS, 2017-26
  • 15 Table 2: Prevalent cases of IBS, by gender, 2017
  • 16 Table 3: Prevalence of IBS, by gender, 2017
  • 19 Table 4: Marketed drugs for IBS
  • 24 Table 5: Pipeline drugs for IBS in the US
  • 27 Table 6: Zelnorm for IBS (July 8, 2019)
  • 28 Table 7: Multiple Drugs for IBS (June 25, 2019)
  • 29 Table 8: Linzess for IBS (June 18, 2019)
  • 30 Table 9: IB-Stim for IBS (June 7, 2019)
  • 32 Table 10: Zelnorm for IBS (October 17, 2018)
  • 33 Table 11: Zelnorm for IBS (October 15, 2018)
  • 42 Table 12: Historical global sales, by drug ($m), 2014-18
  • 42 Table 13: Forecasted global sales, by drug ($m), 2019-23
Back to Top